NASDAQ:CMRX - Chimerix Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.50 -0.16 (-4.37 %)
(As of 05/19/2019 04:16 AM ET)
Previous Close$3.50
Today's Range$3.40 - $3.70
52-Week Range$1.74 - $5.04
Volume363,483 shs
Average Volume517,790 shs
Market Capitalization$178.75 million
P/E RatioN/A
Dividend YieldN/A
Beta1.47
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside for the treatment of norovirus; and CMX157, a nucleoside analog for the treatment of HIV and hepatitis B virus infection. The company has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; and Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Receive CMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CMRX
CUSIPN/A
Phone919-806-1074

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.22 million
Book Value$3.22 per share

Profitability

Net Income$-69,470,000.00
Net Margins-757.77%

Miscellaneous

Employees82
Market Cap$178.75 million
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable

Chimerix (NASDAQ:CMRX) Frequently Asked Questions

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

How were Chimerix's earnings last quarter?

Chimerix Inc (NASDAQ:CMRX) issued its earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.35). The biopharmaceutical company earned $2.36 million during the quarter, compared to analyst estimates of $2 million. Chimerix had a negative net margin of 757.77% and a negative return on equity of 36.85%. View Chimerix's Earnings History.

When is Chimerix's next earnings date?

Chimerix is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Chimerix.

What price target have analysts set for CMRX?

3 brokers have issued 12-month target prices for Chimerix's shares. Their predictions range from $2.00 to $10.00. On average, they anticipate Chimerix's stock price to reach $5.00 in the next year. This suggests a possible upside of 42.9% from the stock's current price. View Analyst Price Targets for Chimerix.

What is the consensus analysts' recommendation for Chimerix?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Chimerix.

Has Chimerix been receiving favorable news coverage?

Media stories about CMRX stock have trended negative on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Chimerix earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future.

Are investors shorting Chimerix?

Chimerix saw a increase in short interest in the month of April. As of April 15th, there was short interest totalling 1,254,184 shares, an increase of 34.1% from the March 29th total of 935,428 shares. Based on an average daily volume of 873,140 shares, the days-to-cover ratio is currently 1.4 days. Approximately 2.8% of the shares of the stock are short sold. View Chimerix's Current Options Chain.

Who are some of Chimerix's key competitors?

What other stocks do shareholders of Chimerix own?

Who are Chimerix's key executives?

Chimerix's management team includes the folowing people:
  • Mr. Timothy W. Trost, Sr. VP, CFO & Corp. Sec. (Age 61)
  • Dr. William Garrett Nichols M.D., MS, Chief Medical Officer (Age 50)
  • Mr. Michael A. Sherman, CEO & Pres (Age 53)
  • Dr. Roy W. Ware Ph.D., MBA, Chief Manufacturing & Technology Officer
  • Dr. Randall Lanier Ph.D., Chief Science Officer

Who are Chimerix's major shareholders?

Chimerix's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (10.92%), BlackRock Inc. (6.30%), Dimensional Fund Advisors LP (5.13%), FMR LLC (3.73%), Morgan Stanley (3.32%) and Renaissance Technologies LLC (2.59%). Company insiders that own Chimerix stock include Ernest Mario, Fred A Middleton, Linda M Richardson and M Michelle Berrey. View Institutional Ownership Trends for Chimerix.

Which institutional investors are selling Chimerix stock?

CMRX stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., FMR LLC, Morgan Stanley, Jacobs Levy Equity Management Inc., Rhenman & Partners Asset Management AB, Spark Investment Management LLC, BlackRock Inc. and Man Group plc. View Insider Buying and Selling for Chimerix.

Which institutional investors are buying Chimerix stock?

CMRX stock was purchased by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Renaissance Technologies LLC, Acadian Asset Management LLC, Parametric Portfolio Associates LLC, Marshall Wace LLP, Connor Clark & Lunn Investment Management Ltd., Oxford Asset Management LLP and M&T Bank Corp. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton and M Michelle Berrey. View Insider Buying and Selling for Chimerix.

How do I buy shares of Chimerix?

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $3.50.

How big of a company is Chimerix?

Chimerix has a market capitalization of $178.75 million and generates $7.22 million in revenue each year. The biopharmaceutical company earns $-69,470,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Chimerix employs 82 workers across the globe.

What is Chimerix's official website?

The official website for Chimerix is http://www.chimerix.com.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]


MarketBeat Community Rating for Chimerix (NASDAQ CMRX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  292 (Vote Outperform)
Underperform Votes:  301 (Vote Underperform)
Total Votes:  593
MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote "Outperform" if you believe CMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel